Revises Outlook for Full-year FORE-SIGHT Growth
Conference Call Begins at 10:00 a.m. Eastern Time Today
BRANFORD, Conn., May 03, 2017 (GLOBE NEWSWIRE) -- CAS Medical Systems, Inc. (NASDAQ:CASM) (CASMED), a leader in medical products for non-invasive patient monitoring of tissue oxygenation, today reported financial results for the three months ended March 31, 2017.
Net sales from continuing operations for the first quarter of 2017 were $5.2 million, compared with $5.5 million for the first quarter of 2016. The Company incurred a net loss applicable to common stockholders for the first quarter of 2017 of $2.2 million, or $0.08 per share. This compares with net income applicable to common stockholders for the first quarter of 2016 of $1.1 million, or $0.04 per share, which included a $1.9 million gain, net of income taxes, on the sale of the Company’s neonatal intensive care product line.
Highlights for the first quarter of 2017, compared with the first quarter of 2016, include the following:
- FORE-SIGHT® disposable sensor sales increased 8% and represented 77% of total sales.
- U.S. FORE-SIGHT sales increased 5%, and U.S. FORE-SIGHT disposable sensor sales increased 8%.
- Net 69 FORE-SIGHT cerebral oximeters were shipped worldwide.
- Net cumulative FORE-SIGHT cerebral oximeters shipped worldwide as of March 31, 2017, increased 21% to 2,157, and the U.S. installed base of monitors increased 21% to 1,158.
- Gross profit margin improved to 54.4% from 52.8%.
- As of March 31, 2017, CASMED had cash, cash equivalents, and borrowings available under its line of credit of $6.5 million.
In the second quarter of 2017, CASMED completed the upgrade and expansion of its U.S. sales organization with the hiring of six sales representatives since the beginning of 2017 and increasing sales territories to 17.
“The modest oximetry growth we’re reporting for the first quarter was both disappointing and below our expectations,” said Thomas M. Patton, President and Chief Executive Officer of CASMED. “However, we are quite pleased to announce our completed expansion and upgrade of our U.S. field sales force. We believe the rebuilding of our sales force was the principal reason for the slow-down in net productivity. We made the decision last year to invest in our sales organization to capitalize on our best-in-class FORE-SIGHT product in a market we estimate will ultimately reach $800 million in the U.S. alone. We entered the quarter with just five tenured sales reps and six newly hired reps but have since hired an additional six reps for a total of 17 staffed territories. Given the expanded talent and scope of these reps, we fully anticipate productivity gains as tenure matures. FORE-SIGHT and its superior clinical performance continue to be very well received by the industry, as evidenced by a standing-room-only crowd at our symposium at the recent Society of Cardiovascular Anesthesiologists annual meeting and the number of sales leads we received.
“Our outlook is for continued growth in our FORE-SIGHT business this year, yet we are revising our guidance to reflect new expectations. We continue to anticipate accelerated growth in the second half of 2017 as our newly hired sales representatives become increasingly productive.”
CASMED revises its outlook for growth in 2017 compared with 2016 as follows:
- Total FORE-SIGHT sales to increase in mid-single-digit percentages;
- Total FORE-SIGHT disposable sensor sales to increase approximately 10% with U.S. FORE-SIGHT sensor sales to increase in mid-teens percentages; and
- U.S. monitor placements to increase in mid-teens percentages.
First-Quarter Financial Results
Net sales from continuing operations for the first quarter of 2017 were $5.2 million, compared with $5.5 million for the first quarter of 2016, with the decrease primarily due to a decline in FORE-SIGHT monitor sales and lower sales of our non-invasive blood pressure products. FORE-SIGHT oximetry sales for the first quarter of 2017 increased 1% to $4.3 million and included a 5% increase in domestic FORE-SIGHT sales to $3.7 million. Disposable sensor sales for the first quarter of 2017 increased 8% over the prior year. FORE-SIGHT sales accounted for 83% of total sales from continuing operations for the first quarter of 2017.
The loss from continuing operations for the first quarter of 2017 was $1.8 million compared with $546,000 for the first quarter of 2016, which was favorably impacted by an income tax benefit of $1.1 million. Gross profit margin for the first quarter of 2017 improved to 54.4% from 52.8% for the prior-year period, due primarily to manufacturing efficiencies and product mix favoring FORE-SIGHT products. Operating expenses for the first quarter of 2017 increased 2% to $4.4 million from the prior-year period, reflecting increased S,G&A costs, and lower clinical R&D spending.
Cash and cash equivalents were $4.7 million as of March 31, 2017, compared with $5.5 million as of December 31, 2016. As of March 31, 2017, $1.8 million of borrowings were available under the Company’s line of credit.
Conference Call Information
CASMED will host a conference call beginning at 10:00 a.m. Eastern Time today to discuss these results and answer questions. Conference call dial-in information is as follows:
- U.S. callers: (866) 239-5859
- International callers: (702) 495-1913
Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Company's website at http://corporate.casmed.com/corporate-info.
A telephone replay will be available from 1:00 p.m. Eastern Time on May 3, 2017, through 11:59 p.m. Eastern Time on May 17, 2017. Replay dial-in information is as follows:
- U.S. callers: (855) 859-2056
- International callers: (404) 537-3406
- Conference ID number (U.S. and international callers): 6276331
- The replay will also be available at www.casmed.com.
About CASMED® – Monitoring What's Vital
CASMED products are designed to provide unique non-invasive monitoring solutions that are vital to patient care. The Company's FORE-SIGHT® Cerebral Oximeters provide a highly accurate, non-invasive measurement of tissue oxygenation in the brain. Direct monitoring of tissue oxygenation can provide a superior and powerful tool to alert clinicians to otherwise unrecognized and dangerously low levels of oxygen in the brain and empower them to improve patient care. In addition to FORE-SIGHT oximeters and accessories, the Company also provides proprietary non-invasive blood pressure monitoring solutions for OEM use. For further information regarding CASMED, visit the Company's website at www.casmed.com.
Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future performance of the Company are subject to many factors including, but not limited to, the customer acceptance of the products in the market, the introduction of competitive products and product development, the impact of any product liability or other adverse litigation, working capital and availability of capital, commercialization and technological difficulties, the impact of actions and events involving key customers, vendors, lenders, competitors, and other risks detailed in the Company’s Form 10-K for the year ended December 31, 2016, and other subsequent Securities and Exchange Commission filings.
Such statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. When used in this press release, the terms "anticipate," "believe," "estimate," "expect," "may," "objective," "plan," "possible," "potential," "project," "will,” and similar expressions identify forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information, or otherwise.
CAS Medical Systems, Inc.
Jeffery A. Baird
Chief Financial Officer
(Tables to follow)
|CAS MEDICAL SYSTEMS, INC.|
|March 31,||December 31,|
|Cash and cash equivalents||$||4,662,897||$||5,488,706|
|Other current assets||324,658||879,365|
|Assets associated with discontinued operations||52,020||85,349|
|Total current assets||9,918,349||11,371,488|
|Property and equipment||9,145,517||8,827,604|
|Less accumulated depreciation||(6,641,029||)||(6,266,097||)|
|Intangible and other assets, net||800,564||790,971|
|Current portion of long-term debt||1,517,921||840,471|
|Liabilities associated with discontinued operations||17,578||92,942|
|Total current liabilities||4,503,424||4,318,352|
|Deferred gain on sale and leaseback of property||57,944||91,603|
|Long-term debt, less current portion, |
less unamortized debt
|Other long-term liabilities||320,000||320,000|
|Series A convertible preferred stock||8,802,000||8,802,000|
|Series A exchangeable preferred stock||5,135,640||5,135,640|
|Additional paid-in capital||31,354,231||30,557,093|
|Total stockholders' equity||2,370,343||3,413,160|
|Total liabilities & stockholders' equity||$||13,223,401||$||14,723,966|
|CAS MEDICAL SYSTEMS, INC.|
|STATEMENTS OF OPERATIONS|
|Three Months Ended|
|March 31, 2017||March 31, 2016|
|Net sales from continuing operations||$||5,224,873||$||5,455,526|
|Cost of sales||2,380,838||2,574,871|
|Research and development||823,593||955,407|
|Selling, general and administrative||3,574,267||3,367,884|
|Total operating expenses||4,397,860||4,323,291|
|Loss from continuing operations before income taxes||(1,813,377||)||(1,637,011||)|
|Income tax expense (benefit)||10,544||(1,091,246||)|
|Loss from continuing operations||(1,823,921||)||(545,765||)|
|(Loss) income from discontinued operations||(30,123||)||175,752|
|Gain on sale of discontinued operations||-||2,942,095|
|Income tax (benefit) expense||(10,544||)||1,091,246|
|(Loss) income from discontinued operations||(19,579||)||2,026,601|
|Net (loss) income||(1,843,500||)||1,480,836|
|Preferred stock dividend accretion||387,006||361,060|
|Net (loss) income applicable to common stockholders||$||(2,230,506||)||$||1,119,776|
|Loss per common share from continuing operations:|
|Basic and diluted||$||(0.08||)||$||(0.03||)|
|Income per common share from discontinued operations:|
|Basic and diluted||$||0.00||$||0.07|
|Per share basic and diluted net (loss) income applicable|
|to common stockholders:||$||(0.08||)||$||0.04|
|Weighted-average number of common shares outstanding:|
|Basic and diluted||27,025,915||26,800,433|
Source:CAS Medical Systems, Inc.